Bridging the gap: Why UK Life Sciences innovation needs capital, not just space
From world-class universities to cutting-edge research clusters in Cambridge, Oxford and London, the UK consistently produces exceptional ideas and intellectual property.
16 June 2026
The UK life sciences sector has long been recognised as a global leader in scientific discovery. Despite this strength, a structural challenge persists: the UK struggles to translate early-stage innovation into fully funded, scalable biotech businesses. The issue is not a lack of science, but a lack of capital at the critical stage where innovation must become investable.
A system built on strong foundations, but weak continuity
The UK excels at the earliest stages of innovation. Seed funding is available, academic output is strong, and new companies are continually being formed. At the other end of the spectrum, later-stage clinical assets can still attract significant investment due to reduced risk and clearer timelines to commercialisation.
However, between these two points lies the industry’s most persistent challenge: the 'valley of death.' This is the stage where companies must scale, validate their science, and progress towards clinical trials. But it's also the stage where funding becomes scarce.
This imbalance is not unique to the UK. Insights from a recent industry visit to Boston – one of the world’s leading biotech hubs – highlighted that even in the US, early growth-stage biotech businesses are facing similar pressures. While the US benefits from a larger capital pool overall, the same investor dynamics are at play: capital is increasingly concentrated in either very early-stage opportunities or de-risked, late-stage assets.
The rise of competing capital
Part of this shift is driven by competition from other sectors – particularly AI and technology. These industries offer significantly shorter return horizons (often under five years) compared to the decade-plus timelines typical of drug development.
For investors, the choice is increasingly clear. Faced with finite resources, many are prioritising sectors with faster and more predictable returns. As a result, life sciences, particularly at the mid-stage, are losing share of available capital.
The UK’s undervalued advantage
Despite these headwinds, the UK holds a clear competitive advantage: cost efficiency.
Biotech companies in the UK can conduct research and development at significantly lower cost than their US counterparts – sometimes by as much as 90%. This creates a compelling opportunity for international investors, particularly from the US, to deploy capital more efficiently while accessing world-class science.
A changing biotech model
The traditional model of biotech is also evolving. Increasingly, companies are operating as 'virtual biotechs'; lean organisations outsourcing lab work and development to contract research organisations (CROs).
This model allows companies to operate with smaller teams and lower overheads, accelerating progress with limited funding. However, it also introduces new risks, including the outsourcing of expertise and intellectual property to overseas markets.
At the same time, investors are showing a growing preference for single-asset companies – focused on one drug, one pathway, and one outcome – over broader platform businesses. While this reduces risk from an investment perspective, it may limit long-term innovation capacity.
The role of AI: opportunity and disruption
AI is beginning to reshape the life sciences landscape, both as a tool and as a competitor for investment. In the near term, its most impactful applications lie in:
- Drug repurposing
- Target identification
- Data-driven discovery
Looking ahead, AI could revolutionise clinical trials through simulation and modelling, dramatically reducing cost and timelines. However, realising this potential depends heavily on regulatory adoption. Until bodies such as the FDA and MHRA fully embrace AI-driven methodologies, its transformative impact will remain largely constrained.
Policy, access and the missing link
A critical barrier to growth in the UK remains structural. Companies face challenges, including access to:
- NHS infrastructure for trials
- UK health data for research
- Scalable follow-on funding
While there is growing recognition of these issues at a policy level, tangible solutions are still emerging. In particular, there is an opportunity to introduce targeted incentives such as tax relief to encourage investment into higher-risk, mid-stage innovation.
Without this, the UK risks continuing to export its most promising ideas before they can fully scale domestically.
The real estate misconception
Within the property sector, there has been significant focus on the delivery of lab space. However, this may be addressing the wrong problem. The limiting factor for growth is not supply of space, but supply of capital.
That said, demand is evolving. Large, highly specified lab spaces are increasingly being taken by AI and tech companies, while early-stage biotech firms are seeking smaller, flexible units often under 5,000 sq ft. This presents a challenge for landlords – how to design financially viable spaces for a fragmented, uncertain tenant base.
A capital-led future
The UK life sciences sector does not lack innovation, talent, or ambition. What it lacks is a consistent flow of capital through the full lifecycle of company growth. If the UK can:
- Attract more international investment
- Implement targeted policy reforms
- Accelerate regulatory innovation
- Better connect its science to capital
Then it has the potential not just to compete globally, but to lead. The opportunity is clear, but the question is whether the ecosystem can evolve quickly enough to capture it.
